VP Hematology (TIME) @TempusAI #PrecisionMedicine #mmsm #lymsm #MDSsm #leusm #CCC19 @COVID19nCCC @ASCO COI: coi.asco.org/share/RBB-TT6R/…
Milwaukee, WI
- Tweets 148,013
- Following 3,999
- Followers 23,003
- Likes 151,817
Pinned Tweet
Whole-Genome Sequencing [WGS] of Pts w/ Myelodysplastic Syndrome Uncovers Novel, Clinically Relevant Biomarkers Missed by Standard-of-Care Methods [8/31/26] @AlexBataller et al. @garciamanero #SOHO2026 MDS-1210
clinical-lymphoma-myeloma-le… #MDSsm #leusm #cagenome @UTMDAnderson @TempusAI
1
1
6
1,165
UCSF’s Kevan Shokat, PhD, just won the $1M Stephenson Global Prize for research in pancreatic cancer. He cracked KRAS, a cancer driver long considered “undruggable.” Drugs built on his work now treat lung and pancreatic cancer. ow.ly/xVlw50ZRSXh
ALT Middle-aged man in a blue lab coat smiling while seated in a scientific laboratory setting.
ALT Hand wearing black glove holding five small glass vials with various colored liquids, including pink and orange hues.
3
300
Mike Thompson, MD, PhD, FASCO retweeted
@RahulBanerjeeMD @DrPMPGI @IMS2026....The spiderman drove straight the take home message..enjoyed the debate ..
1
3
19
759
Mike Thompson, MD, PhD, FASCO retweeted
BCMA×GPRC5D dual-targeted CAR-T therapy BMS-986453 showed >90% response rates at two dose levels in ongoing first-in-human early-phase trial, w/ 100% response 100% MRD-negativity in BCMA/GPRC5d-naïve pts --- Doris Hansen, MD #IMS26
1
11
17
817
Behind on #IMS26 coverage? 👀 Catch up with our daily recaps and exclusive insights from experts, live from Glasgow.
hubs.ly/Q04ylRTc0
543
Mike Thompson, MD, PhD, FASCO retweeted
No!! The cure definition is aspirational. Stopping maintenance for any patient is a decision that’s made based on the patient’s unique clinical situation, myeloma risk features, the treatment administered, duration and depth of MRD negativity, data on duration of maintenance by drug that we have available etc. Not a decision to be taken lightly.
1
9
40
6,018
Mike Thompson, MD, PhD, FASCO retweeted
💯 ORR and 100% MRD negativity among evaluable pts in bcma naive pts, wow! With dual CarT presented by @DorisKHansen #IMS26
13
28
2,174
Mike Thompson, MD, PhD, FASCO retweeted
IsaVRD vs IsaRD
A critical question not answered by any registrational trial of NDMM with CD38 directed Abs.
Love the use of RMST ! Thnx for doing that; a much better marker than absolute PFS
We all agree HRMM need more; but may he Std Risk MM does not need bortezmib and related neuropathy.
We seeing these of projecting 10 yrs out !!
#MMSM #IMS26
@Myeloma_Society
1
4
10
759
Mike Thompson, MD, PhD, FASCO retweeted
RAS ON!
Read: "RAS Pathway Activation Is a Hallmark of Myeloid Sarcoma," by authors Bettina Nadorp, Audrey Lasry, Sanam Loghavi, Iannis Aifantis, and Ann-Kathrin Eisfeld. aacrjournals.org/bloodcancer… @BettinaNadorp @audrey_lasry @sanamloghavi @iannisaifantis1 @AkEisfeld
3
16
1,819
Mike Thompson, MD, PhD, FASCO retweeted
Great presentation of EXCALIBER RRMM by Sagar Lonial
6
20
709
Mike Thompson, MD, PhD, FASCO retweeted
Huge thanks to @HealthTree @PeerView and @Myeloma_Society for allowing me the privilege to talk about immunotherapy sequencing and Oreo cookies at #IMS26. This has been such a wonderful congress ! #mmsm @TischCancer
11
32
1,134
Mike Thompson, MD, PhD, FASCO retweeted
Official drink of #IMS26 in 🏴, home to the first James Bond actor!
“Sequenced, not stirred” - the best of CAR-T and BsAb in myeloma come when both are intentionally available sequentially.
CAR-T ➡️ BsAb beats CAR-T alone even knowing post-CAR-T relapses often end poorly.
Read this recent spotlight by #IMS26 speaker Rahul Banerjee, “Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple Myeloma.” aacrjournals.org/bloodcancer… @rahulbanerjeeMD
4
20
1,709
In the realm of the “e-Patient” it is key to not underestimate your audience [Jul 11, 2017] Sem Hematol ow.ly/gDA130dJre2 #mmsm
510
Twitter 101 & beyond: Intro to social media platforms available to practicing #hemeonc [Jul 11, 2017] @mtmdphd @AhlstromJenny @drdonsdizon @DrYashGad @chimoose @hjluks @andrewschorr Sem Hematol ow.ly/gDA130dJre2 #mmsm
3
509
The Power of Twitter in Multiple Myeloma by @MyelomaTeacher [Sep 6, 2016] - via @myelomacrowd ow.ly/hcGO303YNQ3 #mmsm @HealthtreeMM
1
431
Schooling Herself & Others on Myeloma..." @MyelomaTeacher is a social media rock star" [Aug 25, 2015] @AACR ow.ly/RZGKR #mmsm HT @DanaHolmes911
2
516
Mike Thompson, MD, PhD, FASCO retweeted
#IMS26 @SagarLonialMD presenting EXCALIBER-RRMM. Finally, the Iber-Dd CELMoD data we've been eagerly awaiting!
Rationale for presenting now, he just explained:
Request from 🇺🇸 FDA not to release MRD-CR-based data before their formal approval.
This is why I attend conferences!
3
13
31
1,878
Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities [Jun 28, 2019] @subatomicdoc et al. @JCOCCI_ASCO ow.ly/AxNP30p1P6g #ayacsm #bcsm #btsm #gyncsm #lcsm #mmsm #pancsm
4
316
Organizing Online Health Content: Developing Hashtag Collections... [6/28/19] - @subatomicdoc @pfanderson @mtmdphd @TheLizArmy @JFreemanDaily @audvin @drdonsdizon @CBlotner_ @DavidCookeMD @womenofteal @stales @fischmd @colleen_young @DrAttai @JCOCCI_ASCO ow.ly/AxNP30p1P6g
1
2
314
Mike Thompson, MD, PhD, FASCO retweeted
First RCT results of Etentamig (BCMA bispecifc antibody) presented at Plenary Session #IMS26 @Myeloma_Society @PlasmaCellPete
@myelomaMD
60 mg fixed dose every 4 weeks makes this the easiest bispecific to administer.
Impressive PFS benefit in relapsed refractory myeloma with at least 2 prior lines of therapy. See thread for more details.
2
46
94
5,692
